Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer

Targeted therapies against EGFR, vascular endothelial growth factor, and vascular endothelial growth factor receptor have expanded treatment options for patients with metastatic colorectal cancer (mCRC). Unfortunately, biomarkers to identify patients that are most likely to derive benefit from targe...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Shiven B, Gill, David, Garrido-Laguna, Ignacio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706127/
https://www.ncbi.nlm.nih.gov/pubmed/26770060
http://dx.doi.org/10.2147/OTT.S68558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706127/
https://www.ncbi.nlm.nih.gov/pubmed/26770060
http://dx.doi.org/10.2147/OTT.S68558

Ejemplares similares